Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

January 2026 Dispatch for the CV Team

News Opinion CV Team Dispatch

January 2026 Dispatch for the CV Team

January 16, 2026

Coverage and Use of Impella and Watchman: A Tale of Four Countries

News Daily News

Coverage and Use of Impella and Watchman: A Tale of Four Countries

Michael O'Riordan

March 04, 2025

FDA Approves Colchicine for Decreasing CV Events

News Daily News

FDA Approves Colchicine for Decreasing CV Events

June 20, 2023

FDA Advisors Unconvinced by Lutonix BTK Drug-Coated Balloon

News Daily News

FDA Advisors Unconvinced by Lutonix BTK Drug-Coated Balloon

February 18, 2021

FDA Extends Ticagrelor Indication to High-Risk CAD Primary Prevention

News Daily News

FDA Extends Ticagrelor Indication to High-Risk CAD Primary Prevention

June 01, 2020

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

News Daily News

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Michael O'Riordan

November 01, 2018

Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval

News Daily News

Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval

May 04, 2018

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.